| 000 | 01636 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514224259.0 | ||
| 264 | 0 | _c20050721 | |
| 008 | 200507s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/cncr.21033 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOmuro, Antonio M P | |
| 245 | 0 | 0 |
_aHigh incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. _h[electronic resource] |
| 260 |
_bCancer _cJun 2005 |
||
| 300 |
_a2344-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBrain Neoplasms _xsecondary |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGefitinib |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMeningeal Neoplasms _xsecondary |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aQuinazolines _xtherapeutic use |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Failure |
| 700 | 1 | _aKris, Mark G | |
| 700 | 1 | _aMiller, Vincent A | |
| 700 | 1 | _aFranceschi, Enrico | |
| 700 | 1 | _aShah, Neelam | |
| 700 | 1 | _aMilton, Daniel T | |
| 700 | 1 | _aAbrey, Lauren E | |
| 773 | 0 |
_tCancer _gvol. 103 _gno. 11 _gp. 2344-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.21033 _zAvailable from publisher's website |
| 999 |
_c15511859 _d15511859 |
||